Company intelligence / Profile preview

Nanophoton

Minoh, Osaka, Japan

Ownership: Private
Development stage: Other

Overview

Nanophoton’s Raman microscope systems are market leaders in high-speed, high-resolution molecular imaging with clinical applications in drug analysis and disease research as well as research in material science and nanotechnology. The company was profitable/near break-even at $5M annual revenue as of 2023[1].

Therapeutic areas: Other
Modalities: Device
Industry: Pathology

Partnerships

Bruker (parent company); global university and industrial users; no major pharma alliance disclosed

Beyond the preview

Go deeper on Nanophoton.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanophoton.

Explore the full profile